Document is current
Any future updates will be listed below
-
Authors
Alsaed, Bassel https://orcid.org/0009-0002-6525-8371
Lin, Linh https://orcid.org/0009-0003-3040-062X
Son, Jieun
Li, Jiaqi
Smolander, Johannes
Lopez, Timothy
Eser, Pinar Ö.
Ogino, Atsuko https://orcid.org/0000-0001-9677-362X
Ambrogio, Chiara https://orcid.org/0000-0003-4122-701X
Eum, Yoonji
Thai, Tran
Wang, Haiyun https://orcid.org/0000-0001-8364-8328
Sutinen, Eva
Mutanen, Hilma
Duàn, Hanna https://orcid.org/0000-0001-8318-130X
Bobik, Nina
Borenius, Kristian
Feng, William W. https://orcid.org/0000-0002-8976-5020
Nabet, Behnam https://orcid.org/0000-0002-6738-4200
Mustjoki, Satu https://orcid.org/0000-0002-0816-8241
Laaksonen, Sanna
Eschle, Benjamin K.
Poitras, Michael J.
Barbie, David
Ilonen, Ilkka https://orcid.org/0000-0002-8149-3550
Gokhale, Prafulla https://orcid.org/0000-0002-1974-5921
Jänne, Pasi A. https://orcid.org/0000-0002-7821-4928
Haikala, Heidi M. https://orcid.org/0000-0002-8465-8568
- License Information
-
More Information
Article History
Received: 8 June 2023
Accepted: 10 December 2024
First Online: 2 January 2025
Competing interests
: H.M.H. has been working within the past 3 years as a part-time Medical Advisor for Amgen AB. C.A. received research fees from Revolution Medicines, Aelin Therapeutics, Verastem, Roche and Boehringer-Ingelheim. P.A.J has consulting fees from AstraZeneca, Boehringer-Ingelheim, Pfizer, Roche/Genentech, Takeda Oncology, ACEA Biosciences, Eli Lilly and Company, Araxes Pharma, Ignyta, Mirati Therapeutics, Novartis, LOXO Oncology, Daiichi Sankyo, Sanofi Oncology, Voronoi, SFJ Pharmaceuticals, Takeda Oncology, Transcenta, Silicon Therapeutics, Syndax, Nuvalent, Bayer, Esai, Biocartis, Allorion Therapeutics, Accutar Biotech and Abbvie, Monte Rosa, Scorpion Therapeutics, Merus, Frontier Medicines, Hongyun Biotechnology and Duality; post-marketing royalties from DFCI owned intellectual property on EGFR mutations licensed to Lab Corp; sponsored research agreements with AstraZeneca, Daichi-Sankyo, PUMA, Boehringer Ingelheim, Eli Lilly and Company, Revolution Medicines and Astellas Pharmaceuticals; stock ownership in Gatekeeper Pharmaceuticals. B.N. is an inventor on patent applications related to the dTAG system (WO/2017/024318, WO/2017/024319, WO/2018/148440, WO/2018/148443, and WO/2020/146250). The Nabet laboratory receives or has received research funding from Mitsubishi Tanabe Pharma America, Inc. The remaining authors declare no competing interests.
